iLoF is using a patented platform technology, based on AI and photonics, to build a digital library of nano-scale diseases biomarkers and biological profiles.

We collect "fingerprints" from nano-scale structures in blood and provide personalized, screening and stratification tools in an affordable, fast, portable way.

iLoF, founded in 2019, has already been featured as one of the most disruptive companies in Europe. Is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, iLoF is currently focusing a validated platform technology in one of the biggest epidemics of our times: Alzheimer's, while maintaining ongoing verticals on Digestive Cancer, Stroke and Infectious diseases.